-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DN7hpUmd6qlm2JwGehmcoMUKUjPxQbcAyvKRX40bsM4shWSXgMszZaQiYojvt46q VHh3cmv4iCIPubWCOtfQWA== 0000950123-95-003045.txt : 19951030 0000950123-95-003045.hdr.sgml : 19951030 ACCESSION NUMBER: 0000950123-95-003045 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19951027 SROS: NONE GROUP MEMBERS: JOHNSON & JOHNSON DEVELOPMENT CORP. GROUP MEMBERS: JOHNSON & JOHNSON ET AL SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: LIFECORE BIOMEDICAL INC CENTRAL INDEX KEY: 0000028626 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 410948334 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-35300 FILM NUMBER: 95584741 BUSINESS ADDRESS: STREET 1: 3515 LYMAN BLVD CITY: CHASKA STATE: MN ZIP: 55318-3051 BUSINESS PHONE: 6123684300 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC INC DATE OF NAME CHANGE: 19861214 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN MEDICAL RESEARCH INC DATE OF NAME CHANGE: 19691118 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON ET AL CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 9085240400 SC 13D/A 1 AMENDMENT NO. 1 TO SCH 13D, LIFECORE BIOMEDICAL 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* LIFECORE BIOMEDICAL, INC. ---------------------------- (Name of Issuer) COMMON STOCK, $.01 par value ------------------------------ (Title of Class of Securities) 53218710 -------------- (CUSIP Number) Blair M. Flicker, Esq. Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933 (908) 524-2527 -------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) October 18, 1995 ------------------ (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /. Check the following box if a fee is being paid with the statement / /. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 SCHEDULE 13D CUSIP NO. 032346108 PAGE 2 OF 11 PAGES --------- ----- ---- - ------------------------------------------------------------------------------------------------------------------------------------ 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Johnson & Johnson 22-1024240 - ------------------------------------------------------------------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) / / (B) / / - ------------------------------------------------------------------------------------------------------------------------------------ 3 SEC USE ONLY - ------------------------------------------------------------------------------------------------------------------------------------ 4 SOURCE OF FUNDS* - ------------------------------------------------------------------------------------------------------------------------------------ 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / / - ------------------------------------------------------------------------------------------------------------------------------------ 6 CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey - ------------------------------------------------------------------------------------------------------------------------------------ 7 SOLE VOTING POWER -0- NUMBER OF ------------------------------------------------------------------------------------------------------------ SHARES 8 SHARED VOTING POWER BENEFICIALLY OWNED BY EACH 962,524 REPORTING ------------------------------------------------------------------------------------------------------------ PERSON 9 SOLE DISPOSITIVE POWER WITH -0- ------------------------------------------------------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER 962,524 - ------------------------------------------------------------------------------------------------------------------------------------ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 962,524 - ------------------------------------------------------------------------------------------------------------------------------------ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / - ------------------------------------------------------------------------------------------------------------------------------------ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.45% - ------------------------------------------------------------------------------------------------------------------------------------ 14 TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. 3 SCHEDULE 13D CUSIP NO. 032346108 PAGE 3 OF 11 PAGES --------- ----- ---- - ------------------------------------------------------------------------------------------------------------------------------------ 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Johnson & Johnson Development Corporation 22-2007317 - ------------------------------------------------------------------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) / / (B) / / - ------------------------------------------------------------------------------------------------------------------------------------ 3 SEC USE ONLY - ------------------------------------------------------------------------------------------------------------------------------------ 4 SOURCE OF FUNDS* - ------------------------------------------------------------------------------------------------------------------------------------ 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) / / - ------------------------------------------------------------------------------------------------------------------------------------ 6 CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey - ------------------------------------------------------------------------------------------------------------------------------------ 7 SOLE VOTING POWER -0- NUMBER OF ------------------------------------------------------------------------------------------------------------ SHARES 8 SHARED VOTING POWER BENEFICIALLY OWNED BY EACH 962,524 REPORTING ------------------------------------------------------------------------------------------------------------ PERSON 9 SOLE DISPOSITIVE POWER WITH -0- ------------------------------------------------------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER 962,524 - ------------------------------------------------------------------------------------------------------------------------------------ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 962,524 - ------------------------------------------------------------------------------------------------------------------------------------ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / - ------------------------------------------------------------------------------------------------------------------------------------ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 9.45% - ------------------------------------------------------------------------------------------------------------------------------------ 14 TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. 4 Page 4 of 11 pages Items 1-6 of the Statement on Schedule 13D filed pursuant to Rule 13d-1 (the "Initial Statement on Schedule 13D") of the Rules and Regulations under the Securities and Exchange Act of 1934, as amended, by Johnson & Johnson, a New Jersey corporation, and Johnson & Johnson Development Corporation, a New Jersey corporation, relating to the shares of Common Stock, $.01 par value per share (the "Common Stock") of Lifecore Biomedical, Inc. (the "Company"), are hereby amended and restated as follows: Item 1. Security and Issuer: Common Stock, $.01 par value Lifecore Biomedical, Inc. 3515 Lyman Boulevard Chaska, Minnesota 55318 Item 2. Identity and Background: (a) Johnson & Johnson ("J&J") and Johnson & Johnson Development Corporation ("JJDC"), both New Jersey corporations (b) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (c) The principal business of J&J is health care products. JJDC is a wholly-owned subsidiary of J&J engaged in the venture capital business. The name, citizenship, residence or business address and principal occupation or employment (and the name, principal business and address of any corporation or other organization in which such employment is conducted) of each director and executive officer of J&J and JJDC is set forth on Appendix A hereto. (d),(e) To the best of J&J's knowledge, neither J&J nor any of its directors or executive officers has, during the past five years: (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. To the best of JJDC's knowledge, neither JJDC nor any of its directors or executive officers has, during the past five years: (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, 5 Page 5 of 11 pages decree or final order prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) Not applicable. Item 3. Source and Amount of Funds or Other Consideration: On August 8, 1994, JJDC purchased from the Company 757,396 shares of Common Stock of the Company for an aggregate consideration of $4,000,000, of which $2,600,000 was paid in cash at the closing of the purchase and of which $1,400,000 was paid in cash previously deposited with the Company by Ethicon, Inc. ("Ethicon"), a wholly-owned subsidiary of J&J. Simultaneous with the closing of such purchase, Ethicon assigned to JJDC all of its right, title and interest to any of such Common Stock. On October 18, 1995, JJDC purchased from the Company 205,128 shares of Common Stock of the Company for $2,000,000. No funds were borrowed to finance either purchase described above. Item 4. Purpose of Transaction: The shares of Common Stock were acquired from the Company for investment purposes. Neither J&J nor JJDC presently has a plan or intention to seek to acquire control of the Company. 6 Page 6 of 11 pages Item 5. Interest in Securities of the Issuer: As of October 27, 1995, J&J and JJDC each had beneficial ownership of an aggregate of 962,524 shares of Common Stock. Based upon the shares of Common Stock outstanding, as indicated in the Company's Prospectus dated October 13, 1995, 962,524 shares constitute approximately 9.45% of the outstanding shares of Common Stock. Item 6. Contracts, Arrangements, etc.: The shares of Common Stock purchased on August 8, 1994 were purchased by JJDC pursuant to a Stock Purchase Agreement dated as of such date between the Company, JJDC and Ethicon. The shares of Common Stock purchased on October 18, 1995 were purchased by JJDC pursuant to a Purchase Agreement dated October 12, 1995 between the Company and JJDC. 7 Page 7 of 11 pages Item 7. Exhibits: Exhibit 7.1 - Stock Purchase Agreement dated as of August 8, 1994 between the Company, JJDC and Ethicon. Previously filed as an exhibit to the Initial Statement on Schedule 13D. Exhibit 7.2 - Purchase Agreement dated October 12, 1995 between the Company and JJDC. Incorporated by reference to Exhibit 1.2 to Amendment No. 1 to Form S-2 of the Company, Registration No. 33-62223, filed on October 10, 1995. 8 Page 8 of 11 pages SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. JOHNSON & JOHNSON DEVELOPMENT CORPORATION By: /s/ B.M. Flicker ------------------- B.M. Flicker Secretary Date: October 27, 1995 JOHNSON & JOHNSON By: /s/ P.S. Galloway ------------------- P.S. Galloway Secretary Date: October 27, 1995 9 CUSIP 53218710 Page 9 of 11 Pages APPENDIX A Board of Directors and Executive Officers of Johnson & Johnson The directors and executive officers of Johnson & Johnson are identified in the table below. Directors of Johnson & Johnson are indicated by an asterisk.
NAME BUSINESS ADDRESS CITIZENSHIP PRINCIPAL OCCUPATION ---- ---------------- ----------- -------------------- 1 . Professor Sir James Black(*) The James Black Foundation United Kingdom Professor and Head of the 68 Half Moon Lane Department of Analytical Dulwich, London SE249JE Pharmacology at the Rayne England Institute, King's College School of Medicine, Chairman of the James Black Foundation 2 . Dr. Gerard N. Burrow(*) Yale New Haven School of United States Dean of the Yale University Medicine School of Medicine since 1992 333 Cedar Street New Haven, CT 06510 3 . Joan Ganz Cooney(*) Children's Television Workshop United States Chairman, Children's Television One Lincoln Plaza Workshop New York, NY 10023 4. James G. Cullen BellAtlantic Corporation United States Vice Chairman 1310 North Court House Road Bell Atlantic Corporation Arlington, VA 22201 5. Roger S. Fine Johnson & Johnson United States Corporate Vice President, One Johnson & Johnson Plaza Administration, and Member, New Brunswick, NJ 08933 Executive Committee of Johnson & Johnson 6 . George S. Frazza Johnson & Johnson United States Vice President and General One Johnson & Johnson Plaza Counsel and Member, Executive New Brunswick, NJ 08933 Committee of Johnson & Johnson 7 . Ronald G. Gelbman Johnson & Johnson United States Member, Executive Committee of One Johnson & Johnson Plaza Johnson & Johnson New Brunswick, NJ 08933 8. Philip M. Hawley(*) Philip M. Hawley United States Former Chairman and Chief Suite 2280 Executive Officer of Carter 444 South Flower Street Hawley Hale Stores, Inc. Los Angeles, CA 90071-2900 9. Clark H. Johnson(*) Johnson & Johnson United States Member, Executive Committee and One Johnson & Johnson Plaza Vice President, Finance of New Brunswick, NJ 08933 Johnson & Johnson 10. Ann Dibble Jordan(*) Johnson & Johnson United States Director of various other One Johnson & Johnson Plaza corporations New Brunswick, NJ 08933 11. Christian A. Koffmann Johnson & Johnson France Member, Executive Committee of One Johnson & Johnson Plaza Johnson & Johnson New Brunswick, NJ 08933 12. Arnold G. Langbo(*) 111 Capital Avenue, S.W. Canada Chairman of the Board and Chief Battle Creek, MI 49015 Executive Officer of the Kellogg Company
10 CUSIP 53218710 Page 10 of 11 Pages
NAME BUSINESS ADDRESS CITIZENSHIP PRINCIPAL OCCUPATION ---- ---------------- ----------- -------------------- 13. Ralph S. Larsen(*) Johnson & Johnson United States Chairman, Board of Directors, One Johnson & Johnson Plaza Chief Executive Officer and New Brunswick, NJ 08933 Chairman, Executive Committee, of Johnson & Johnson 14. James T. Lenehan Johnson & Johnson United States Member, Executive Committee of One Johnson & Johnson Plaza Johnson & Johnson New Brunswick, NJ 08933 15. Dr. John S. Mayo(*) AT&T Bell Laboratories, Inc. United States President, Emeritus, AT&T Bell 600 Mountain Avenue Laboratories, Inc. Murray Hill, NJ 07974 16. Thomas S. Murphy(*) Capital Cities/ABC, Inc. United States Chairman of the Board and Chief 77 West 66th Street Executive Officer of Capital New York, NY 10023-6298 Cities/ABC 17. Paul J. Rizzo (*) IBM Corporation United States Retired Vice Chairman of Old Orchard Road International Business Machines Armonk, NY 10504 Corporation 18. Maxine F. Singer, Ph.D.(*) Carnegie Institution of United States President of the Carnegie Washington Institution of Washington 1530 P Street, N.W. Washington, D.C. 20005-1910 19. Roger B. Smith (*) United States Retired Chairman of General Johnson & Johnson Motors Corporation, Member of the One Johnson & Johnson Plaza Business Council and Trustee of New Brunswick NJ 08933 the Alfred P. Sloan Foundation 20. Robert N. Wilson(*) Johnson & Johnson United States Vice Chairman, Board of Directors One Johnson & Johnson Plaza and Vice Chairman, Executive New Brunswick, NJ 08933 Committee of Johnson & Johnson
11 CUSIP 53218710 Page 11 of 11 Pages BOARD OF DIRECTORS AND EXECUTIVE OFFICERS OF JOHNSON & JOHNSON DEVELOPMENT CORPORATION The directors and executive officers of Johnson & Johnson Development Corporation are identified in the table below. Directors of Johnson & Johnson Development Corporation are indicated by an asterisk.
NAME BUSINESS ADDRESS CITIZENSHIP PRINCIPAL OCCUPATION ---- ---------------- ----------- -------------------- 1. William L. Brower, Jr.(*) McNeil Consumer Products United States Vice President Finance, Company McNeil Consumer Products Camp Hill Road Company Fort Washington, PA 19034 2. Blair M. Flicker(*) Johnson & Johnson United States General Attorney of Johnson & One Johnson & Johnson Plaza Johnson and Secretary of New Brunswick, NJ 08933 Johnson & Johnson Development Corporation 3. Peter S. Galloway Johnson & Johnson United States Vice President of Johnson & Johnson One Johnson & Johnson Plaza Development Corporation New Brunswick, NJ 08933 Secretary and Associate General Counsel of Johnson & Johnson 4. Dr. Robert Gussin(*) Johnson & Johnson United States Vice President, Science and One Johnson & Johnson Plaza Technology of Johnson & New Brunswick, NJ 08933 Johnson 5. Edward J. Hartnett(*) Johnson & Johnson United States Company Group Chairman, One Johnson & Johnson Plaza Johnson & Johnson New Brunswick, NJ 08933 6. Susan Lambert(*) Johnson & Johnson United Vice President of One Johnson & Johnson Plaza Kingdom Johnson & Johnson Development New Brunswick, NJ 08933 Corporation 7. Ting Pau Oei(*) Johnson & Johnson United States Vice President of One Johnson & Johnson Plaza Johnson & Johnson Development New Brunswick, NJ 08933 Corporation 8. Peter T. Tattle(*) Johnson & Johnson Canada Company Group Chairman, One Johnson & Johnson Plaza Johnson & Johnson New Brunswick, NJ 08933 9. James R. Utaski(*) Johnson & Johnson United States Corporate Vice President, One Johnson & Johnson Plaza Business Development of New Brunswick, NJ 08933 Johnson & Johnson; President of Johnson & Johnson Development Corporation 10. Dr. Brad Vale(*) Johnson & Johnson United States Vice President of One Johnson & Johnson Plaza Johnson & Johnson Development New Brunswick, NJ 08933 Corporation
-----END PRIVACY-ENHANCED MESSAGE-----